Rodrigo Machado-Vieira

5PUBLICATIONS
52CO-AUTHORS
Biologically active moleculesBiomolecular modelling and designGene and molecular therapyClinical pharmacology and therapeuticsMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 28, 2026
Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

|Mar 25, 2026
Explainable drug side effect prediction in central neural system via biologically informed graph neural network.

Tongtong Huang, Ko-Hong Lin, Rodrigo Machado-Vieira

|May 12, 2023
The case for reverse engineering ketamine and psychedelics: lessons from translational oncology. A Response to Miller et al. "Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies".

Gregory Jones, Rodrigo Machado-Vieira

|Jan 13, 2021
Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.

Rodrigo Machado-Vieira, João Quevedo, Lokesh Shahani

|May 20, 2020
Brain aging in major depressive disorder: results from the ENIGMA major depressive disorder working group.

Laura K M Han, Richard Dinga, Tim Hahn

Pageof 1

Frequent Collaborators

2 joint publications

Jair C Soares

1 joint publications

Laura K M Han

1 joint publications

Lisa T Eyler

1 joint publications

Ivan Brak